| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines.
|
J Natl Compr Canc Netw
|
2013
|
3.03
|
|
2
|
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
|
J Clin Oncol
|
2007
|
2.51
|
|
3
|
Esophageal and esophagogastric junction cancers.
|
J Natl Compr Canc Netw
|
2011
|
2.03
|
|
4
|
Esophageal and esophagogastric junction cancers, version 1.2015.
|
J Natl Compr Canc Netw
|
2015
|
1.52
|
|
5
|
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
|
JOP
|
2012
|
1.32
|
|
6
|
Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.
|
Oncologist
|
2005
|
1.21
|
|
7
|
Overexpression of OATP1B3 confers apoptotic resistance in colon cancer.
|
Cancer Res
|
2008
|
1.20
|
|
8
|
Anti-angiogenic treatment of gastrointestinal malignancies.
|
Cancer Invest
|
2005
|
1.14
|
|
9
|
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
|
Clin Cancer Res
|
2006
|
1.08
|
|
10
|
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2016
|
0.99
|
|
11
|
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.
|
Invest New Drugs
|
2008
|
0.98
|
|
12
|
Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids.
|
Cancer Res
|
2014
|
0.95
|
|
13
|
A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells.
|
Mol Pharm
|
2012
|
0.95
|
|
14
|
Novel targets in esophageal and gastric cancer: beyond antiangiogenesis.
|
Expert Opin Investig Drugs
|
2009
|
0.89
|
|
15
|
A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
|
J Cancer Ther
|
2013
|
0.88
|
|
16
|
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
|
Cancer Chemother Pharmacol
|
2014
|
0.84
|
|
17
|
A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer.
|
Gastrointest Cancer Res
|
2012
|
0.82
|
|
18
|
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.
|
Cancer Chemother Pharmacol
|
2007
|
0.81
|
|
19
|
Administration of oxaliplatin to a pregnant woman with rectal cancer.
|
Cancer Chemother Pharmacol
|
2008
|
0.80
|
|
20
|
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
|
Clin Colorectal Cancer
|
2008
|
0.79
|
|
21
|
The epidermal growth factor receptor as a target for gastrointestinal cancer therapy.
|
Curr Treat Options Oncol
|
2004
|
0.78
|
|
22
|
Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy.
|
AAPS J
|
2015
|
0.78
|
|
23
|
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.
|
Target Oncol
|
2014
|
0.78
|
|
24
|
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.
|
Onco Targets Ther
|
2009
|
0.76
|
|
25
|
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.
|
Am J Clin Oncol
|
2008
|
0.76
|
|
26
|
A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.
|
Cancer Chemother Pharmacol
|
2014
|
0.75
|
|
27
|
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.75
|
|
28
|
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.
|
Invest New Drugs
|
2008
|
0.75
|
|
29
|
A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.
|
Radiother Oncol
|
2005
|
0.75
|
|
30
|
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.
|
Invest New Drugs
|
2010
|
0.75
|